Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors

Exclusion Criteria

• •Pregnant or nursing females.
• •Treatment with any investigational drug within 4 weeks prior to the first dose of study drug
• •Grade ≥ 3 immune-related adverse events (irAE) or irAE that lead to discontinuation of prior immunotherapy. Untreated or uncontrolled central nervous system (CNS) tumors or metastases
• •Any active autoimmune disease or documented history of autoimmune disease.
• •Infection of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
• •Subjects requiring systemic treatment with corticosteroids or other immunosuppressive medications within 21 days before the planned first dose of study drug.
• •Current or prior history of pneumonitis, hepatitis, nephritis, colitis or thyroiditis. Peripheral neuropathy ≥ Grade 2.
• •History of clinically significant cardiac disease.
• •Uncontrolled current illness.